Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06279364). This is a study registration, not published results. Lead sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 537 participants (ACTUAL). Conditions: Triple Negative Breast Cancer. Interventions: DRUG: SKB264; DRUG: Paclitaxel; DRUG: Nab-paclitaxel; DRUG: Capecitabine; DRUG: Eribulin; DRUG: Carboplatin. Primary outcome measures: Overall Survival (OS) , Randomization up to approximately 40 months; Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) , Randomization up to approximately 28 months. Brief summary: The aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell death ligand 1 (PD-L1) or in patients with PD-L1 positive tumors who received prior anti-programmed cell death 1 (PD-1)/PD-L1 inhibitor in early setting